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Perﬂuorooctanoic acid (PFOA) is a perﬂuoro-
alkyl acid (PFAA) polymerization aid used in
the manufacture of ﬂuorinated polymers and
elastomers. The resulting fluorinated com-
pounds are used in myriad consumer and
industrial products, including nonstick, stain-
repellant, water-repellant, and fire-retardant
coatings. PFOA is also a known breakdown
product of fluorinated telomer alcohols and
other precursor compounds of fluorinated
polymers (Wang et al. 2005). Production of
PFOA worldwide exceeded 1,000 metric tons
in 2004, and it is widely distributed and per-
sistent in the environment. The presence of
PFOA in serum and tissues of humans and
wildlife indicate that exposure to PFOA is
widespread.
Levels of PFOA in wildlife range from
0.05 ng/mL in the blood of cod collected from
European waters (Falandysz et al. 2006) to
8.14 ng/mL in plasma of loggerhead sea turtles
from North America (Keller et al. 2005).
Human serum concentrations vary depending
on the population evaluated: PFOA concentra-
tions between 4.8 and 5.5 ng/mL were
reported in the general U.S. population
(Calafat et al. 2007), whereas a population liv-
ing near a fluoropolymer production facility
had values of 386–824 ng/mL for occupa-
tional exposures and 307–458 ng/mL for envi-
ronmental exposures (Emmett et al. 2006).
Epidemiologic studies to explore potential
human health effects are ongoing (Fletcher
et al. 2007).
Liver toxicity is commonly reported in
exposed laboratory animals. Hepatomegaly
and hepatic peroxisome proliferation have
been described in monkeys (Butenhoff et al.
2002) and in various strains of mice (Kudo
et al. 2006; Yang et al. 2000, 2001) and rats
(Biegel et al. 2001; Kudo et al. 2000;
Palazzolo 1993). Liver, Leydig cell (testis), and
acinar cell (pancreas) tumors have also been
reported in rodents (Biegel et al. 2001; Cook
et al. 1999). Immunotoxicity has also been
reported (Yang et al. 2000, 2001, 2002). In
addition, numerous developmental effects,
including neonatal mortality, postnatal
growth impairment, developmental delays,
and retarded growth, have recently been
reported (Lau et al. 2006; White et al. 2007;
Wolf et al. 2007).
Lymphoid tissue atrophy (Yang et al.
2000, 2001) and reduced de novo antibody
synthesis (Yang et al. 2002) have been
observed in C57BL/6 mice following dietary
exposure to PFOA. Thus, a preliminary risk
assessment by the U.S. Environmental
Protection Agency (EPA) identiﬁed immuno-
suppression as an end point of concern; a sub-
sequent review of the risk assessment by the
U.S. EPA Science Advisory Board (U.S. EPA
2006) recommended that immune system
effects be considered for quantitative risk
assessment. The level of U.S. EPA interest and
lack of corroborating studies warranted a more
thorough assessment. We therefore evaluated
both humoral and cell-mediated immune
function in experiments designed to corrobo-
rate the reported altered immune function
observed in C57BL/6 mice and to establish no
observed adverse effect level (NOAEL) and
lowest observed adverse effect level (LOAEL)
values from dose–response studies of immune
function.
Materials and Methods
Animals. We used the C57BL/6 mouse
strain for consistency with the studies of
Yang et al. (2000, 2001, 2002). C57BL/6J
female mice (6–7 weeks of age) were pur-
chased for the initial (recovery) study from
the Jackson Laboratories (Bar Harbor, ME).
However, during the course of that study,
many of the mice had skin lesions. We later
learned that C57BL/6J mice have become
genetically susceptible to ulcerative dermatitis.
Thus, for the dose–response studies, we pur-
chased C57BL/6N female mice (6–7 weeks of
age) from Charles River Laboratories (Raleigh,
NC). Once at the U.S. EPA’s animal care
facilities (accredited by the Association for
Assessment and Accreditation of Laboratory
Animal Care), animals were housed in groups
of eight in polycarbonate cages with hardwood
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BACKGROUND: Perﬂuorooctanoic acid (PFOA), an environmentally persistent compound of regula-
tory concern, has been reported to reduce antibody responses in mice at a single dose.
OBJECTIVE: The aim of this study was to evaluate PFOA effects on humoral and cellular immunity
using standard assays for assessing immune function, and to derive dose–response data.
METHODS: C57BL/6J mice received 0 or 30 mg PFOA/kg/day for 10 days; half of the exposed
groups were switched to vehicle and half continued on PFOA for five days. C57BL/6N mice
received 0–30 mg/kg/day of PFOA in drinking water for 15 days. Mice were immunized with
sheep red blood cells or sensitized to bovine serum albumin in Freund’s complete adjuvant on day
10 of exposure; immune responses were determined 1 day post-exposure.
RESULTS: We found that 30 mg PFOA/kg/day given for 10 or 15 days reduced IgM synthesis;
serum collected 1 day postexposure contained 8.4 × 104 or 2.7 × 105 ng PFOA/mL, respectively.
IgM synthesis was suppressed at exposures ≥ 3.75 mg PFOA/kg/day in a dose-dependent manner,
and IgG titers were elevated at 3.75 and 7.5 mg PFOA/kg/day. Serum PFOA at 3.75 mg/kg/day
was 7.4 × 104 ng/mL 1 day postexposure, or 150-fold greater than the levels reported in individuals
living near a PFOA production site. Using a second-degree polynomial model, we calculated a
benchmark dose of 3 mg/kg/day, with a lower bound (95% conﬁdence limit) of 1.75 mg/kg/day.
Cell-mediated function was not affected.
CONCLUSIONS: IgM antibodies were suppressed after PFOA exposure. The margin of exposure for
reduced IgM antibody synthesis was approximately 150 for highly exposed human populations.
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Products, Warrensburg, NY). They were
provided a 12-hr light:dark cycle (light,
0600–1800 hours; dark, 1800–0600 hours),
maintained at 22.3 ± 1.1°C and 50 ± 10%
humidity, and given ad libitum access to both
food (5P00 Prolab RMH 3000; PMI
Nutrition International, Richmond, IN) and
water. Animals were acclimated for at least
10 days before dosing began. All procedures
employed in this study were approved in
advance by the Institutional Animal Care and
Use Committee of the National Health and
Environmental Effects Research Laboratory,
U.S. EPA; all animals were treated humanely
and with regard for alleviation of suffering.
Recovery study. Dosing solutions.
PFOA was purchased from Fluka Chemical
(Steinhiem, Switzerland) as its ammonium
salt (≥ 98% purity, lot 421207/1 319030).
PFOA dosing solutions were prepared fresh
twice weekly in deionized water at a concen-
tration of 3 mg/mL. Vehicle control mice
received water vehicle by gavage once daily for
15 days. Experimental groups were exposed to
30 mg PFOA/kg body weight (BW) per day
by gavage for 10 days; on days 11–15 of dos-
ing, half of the mice receiving PFOA were
switched to the water vehicle (recovery group)
and the other half continued receiving PFOA
(constant group; Figure 1). We chose the dose
of 30 mg/kg/day because Yang et al. (2000,
2001, 2002) reported that this dose reduced
lymphoid organ weights and production of
antigen-speciﬁc antibodies over a similar time
period.
Experimental design. Animals were ran-
domly divided into 40 animals/end point and
8 animals/dose group. Animals were weighed
twice weekly during the dosing period and
also just before sacriﬁce. We conducted cellu-
lar and humoral immune function assays in
separate groups of animals. Cage controls
were included with each end point group to
ensure that gavage treatment did not alter
experimental results and, with the exception
of gavage exposure, were treated identically to
all other mice within end point groups.
Antibody synthesis (IgM and IgG).
Animals (16/dose) were immunized on the
11th day of dosing by intravenous injection of
4.0 × 107 sheep red blood cells (SRBCs) in
0.2 mL sterile saline. Five days later, 8 animals/
dose were anesthetized with carbon dioxide
and exsanguinated by neck vein transection.
Blood was collected and held at room temper-
ature for 30 min, centrifuged at 4°C to sepa-
rate serum, and serum was frozen at –80°C
until analysis of SRBC-specific IgM. Two
weeks after primary immunization, the
remaining 8 animals/dose were given a
booster immunization of SRBCs (4.0 × 107).
Five days later, animals were anesthetized
with carbon dioxide and exsanguinated by
neck vein transection. Blood was processed as
described above for later analysis of SRBC-
specific IgG. The relative serum titers of
SRBC-speciﬁc IgM and IgG antibodies were
measured by ELISA as described below.
IgM titers were determined as described
previously (DeWitt et al. 2005). Brieﬂy, ﬂat-
bottom 96-well Immunolon-2 ELISA
microtiter plates (Dynatech Labs, Chantilly,
VA) were coated with 125 µL of 2 µg/mL of
SRBC membrane [1.46 mg/mL stock solution
diluted in phosphate-buffered saline (PBS);
prepared according to Temple et al. (1995)]
and then incubated at 4°C for at least 16 hr.
Each plate included 20 wells that were coated
with pooled serum collected from healthy mice
5 days after primary immunization with
SRBCs, and 16 wells contained 100 µL PBS as
blanks. After washing, blocking of nonspeciﬁc
binding, and addition of serum samples (seri-
ally diluted from 1:8 to 1:4,096), secondary
antibody (goat anti-mouse IgM horseradish
peroxidase; Accurate Chemical and Scientiﬁc
Corp., Westbury, NY) was added. Following
three washes and addition of substrate [one
tablet of 2,2´-azino-di-(3 ethylbenzthiazoline
sulfonic acid) (ABTS; Sigma Chemical
Company, St. Louis, MO); added to 50 mL
phosphate-citrate buffer with one tablet of urea
hydroxide peroxide (Sigma) in 100 mL of dis-
tilled water], plates were incubated for 45 min
at room temperature and then read at 410 nm
on a SpectraMax 350 plate reader (Molecular
Devices, Sunnyvale, CA).
The concentration of SRBC-speciﬁc IgG
was evaluated using the same quantitative assay
as for IgM with the following exceptions: The
internal control for IgG was generated by serial
dilution (from 1:8 to 1:4,096) of 100 µL
pooled serum collected from healthy mice
5 days after a second immunization with
SRBCs; F(ab´)2 goat anti-mouse IgG horse-
radish peroxidase (Accurate Chemical and
Scientiﬁc Corp., Westbury, NY) was used as
the secondary antibody. Absorbance was read
on a SpectraMax 350-plate reader at 410 nm.
Both IgM and IgG antibody titers were
processed using SOFTmax Pro software
(Molecular Devices) to determine the log2
serum titer for an optical density of 0.5 units
from the log–log curve of optical density versus
dilution, as described by Temple et al. (1995).
Delayed-type hypersensitivity responses
(DTH). Eight animals per dose were used to
measure the DTH responses to puriﬁed (frac-
tion V) bovine serum albumin (BSA; Sigma).
BSA (2 mg/mL in sterile saline) was emulsiﬁed
in Freund’s complete adjuvant (CFA; Difco,
Detroit, MI) at a 1:1 ratio. Animals anes-
thetized with isoﬂurane were sensitized on the
11th day of dosing by injecting 0.05 mL
BSA-CFA subcutaneously into the caudal tail
fold. After 7 days animals were anesthetized
with isoflurane and challenged by injecting
0.05 mL of heat-aggregated BSA into the right
rear footpad. The left rear footpad was injected
with the same volume of saline and served as
the injection control. BSA was aggregated by
heating 40 mg BSA/mL of sterile saline to
75°C for 1 hr and removing excess saline by
centrifuging for 10 min at 450 × g. After 24 hr,
footpad thickness (triplicate measurements)
was determined in anesthetized animals with
an electronic caliper designed and built in 
the model shop at the U.S. EPA (Research
Triangle Park, NC). The device applies very
light, even, and reproducible pressure on the
footpad for each measurement, thus increasing
the accuracy of measurements. Standards of
known thickness were measured before and
after experimental measurements. Swelling was
calculated by subtracting the mean saline-
injected, left footpad thickness from the mean
BSA-injected right footpad thickness.
Lymphoid organ weights. Lymphoid
organs (spleen and thymus) were removed
from animals that were bled for IgM (1 day
after exposure ended) and IgG (15 days after
exposure ended) for antibody determinations.
The organs were immediately weighed and
archived at –80°C.
Dose–response study I. Dosing solutions.
PFOA drinking water dosing solutions were
prepared fresh twice weekly in deionized water
at concentrations of 200, 100, 50, and
25 mg/L (to provide doses of 30, 15, 7.5, and
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Figure 1. Study design of recovery and dose–response studies.
PFOA constant (PFOA for 15 days)
PFOA recovery (PFOA for 10 days)
PFOA dose response (PFOA for 15 days)
Day 11 of exposure: immunized with SRBCs or sensitized with BSA in CFA
1 Day postexposure: collected organs and sera for IgM
3 Days postexposure: challenged with heat-aggregated BSA
4 Days postexposure: measured footpad swelling for DTH
10 Days postexposure: booster immunizations with SRBCs
15 Days postexposure: collected organs and sera for IgG
(Water for 5 days)
Day 1 Day 10 Day 11 Day 153.75 mg/kg/day, respectively, based on aver-
age daily water consumption rates and animal
body weights). A 200-mg/L solution was ini-
tially prepared by adding PFOA to deionized
water and mixing for 5 min. Lower concen-
trations were made by serial dilutions in
deionized water. Dosing solutions were mixed
in 25-L polycarbonate carboys and then
transferred into individually labeled plastic
drinking water bottles topped with double
ball-bearing sipper tubes. Actual PFOA con-
centrations in the dosing solutions were deter-
mined by liquid chromatography-tandem
mass spectrophotometry (LC-MS/MS) analy-
sis and were 224.0 ± 9.1, 109.8 ± 7.6,
53.8 ± 4.8, and 29.7 ± 2.8 mg PFOA/L for
target concentrations of 200, 100, 50, and
25 mg/L, respectively. Time-course sampling
of water from the dosing solutions over a
4-day period (the maximum time water bot-
tles remained on cages) revealed no signiﬁcant
changes in PFOA concentrations. Mice
received PFOA-containing drinking water for
15 consecutive days (Figure 1). Dosing water
was changed and water consumption per cage
(based on water bottle weights) was recorded
twice weekly. Vehicle controls received deion-
ized water for 15 days. Daily PFOA exposure
was calculated based on average water
consumption per cage. All procedures for
dose–response study I were performed twice,
with two different groups of animals. All
other procedures were identical to those
performed in the recovery study.
Dose–response study II. Dosing solutions.
The same procedures employed in dose–
response study I were used in dose–response
study II, with the exception of dosing solution
concentrations; PFOA concentrations were 50,
25, 12.5, and 6.25 mg/L (to provide doses of
7.5, 3.75, 1.88, and 0.94 mg/kg/day, respec-
tively, based on average daily water consump-
tion rates). Vehicle controls received deionized
water for 15 days. All dosing procedures for
dose–response study II were performed twice,
with two different groups of animals. All other
procedures were identical to those performed
in the recovery study.
Serum PFOA concentrations. Sample
preparation. We determined PFOA concen-
trations in aliquots of serum collected for
measurement of IgM and IgG titers. Samples
from the recovery study and from dose–
response study I were prepared in a fashion
similar to that of Lau et al. (2006). In brief,
serum samples were thawed by placement in
cool water and vortexed 30 sec before with-
drawing an aliquot (10–25 µL). The aliquot
was then placed into a 15-mL polypropylene
tube (Falcon tube; BD, Franklin Lakes, NJ).
Serum from control animals. Serum was
deprotonated with 200 µL 0.1 M formic acid.
Samples were then vigorously vortexed for
30 sec and spiked with a 2-mL aliquot of cold
acetonitrile containing 1.25 ng 13C2-PFOA to
precipitate the proteins. Samples were cen-
trifuged at 5,000 rpm for 5 min to pelletize
proteins, and the supernatant was decanted to
a new tube and diluted with 20 mL of fresh
deionized water. Samples were concentrated
and cleaned up using a Waters (Milford,
MA) HLB SPE (hydrophilic-lipophilic bal-
ance, solid-phase extraction) column (3 cc,
60 mg) with a water wash and a methanol
extraction. Methanolic extracts were then
reduced under N2 gas to an appropriate vol-
ume using a Zymark N-Evap (Organomation
Associates Inc., Berlin, MA). The analytes
were redissolved in equal volume of 2 mM
ammonium acetate and acetonitrile for
LC/MS-MS analysis.
Serum from dosed animals. Serum was
diluted and deprotonated with 10 mL of 0.1 M
formic acid. Samples were shaken for 1 hr; a
1-mL aliquot was then removed and diluted
with cold acetonitrile containing 100 ng
13C2-PFOA. After shaking (30 min), a 200-µL
aliquot was removed and combined with 2 mM
ammonium acetate for LC/MS-MS analysis.
Standard curve and quality assurance/
quality control (QA/QC). The standard
curve preparation was matrix matched.
Standards were prepared by placing 10–25 µL
of control Pel-Freez CD1 mouse serum (Pel-
Freez Biologicals, Rogers, AR) in a 15-mL
polypropylene tube and adding a known
mass of PFOA in methanol relating to
1–200 ng PFOA/mL serum for controls and
10,000–300,000 ng PFOA/mL serum for
dosed animals. QA/QC samples were pre-
pared in advance in a batch of Pel-Freez CD1
mouse serum at 25 and 100 ng/mL for control
animal sera and 25,000 and 100,000 ng/mL
for dosed animal sera. The average accuracy
DeWitt et al.
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Table 1. Serum concentrations (mean ± SE) of PFOA from female mice exposed for 15 days, with serum
collected 1 or 15 days postdosing (PD).
1 Day PD (ng/mL) 15 Days PD (ng/mL)
Recovery studya
Cage control 25.2 ± 2.0*a 614.9 ± 66.6a
Vehicle control 32.8 ± 19.5a 24.7 ± 2.0a
Recovery 84,700 ± 9,814b 47,757 ± 2,115b
Constant 266,500 ± 23,018c 67,988 ± 3,853c
Dose–response studyb
0 mg/kg 54.3 ± 4.9a 156.4 ± 14.9a
3.75 mg/kg 74,913 ± 2,667b 35,325 ± 1,607b
7.5 mg/kg 87,150 ± 3,296b,c 42,771 ± 1,708b
15 mg/kg 128,125 ± 6,818c 50,025 ± 1,486b,c
30 mg/kg 162,625 ± 8,434d 52,713 ± 3,212c
aC57BL/6J mice were treated with PFOA by gavage; serum from recovery groups was collected 6 (1 day PD) or 20 (15 days
PD) days after the last PFOA dose was administered. bC57BL/6N mice were treated with PFOA in drinking water. *Within
1-day or 15-days PD groups, means followed by a different letter are statistically different (p < 0.05).
Figure 2. Effects of PFOA exposure on BW (mean ± SE) of female C57BL/6J (A) or C57BL/6N (B,C) mice. PD, postdosing. (A) Effects of PFOA administered via gav-
age to C57BL/6J mice for 10 days (PFOA-recovery group) or 15 days (PFOA-constant group). Mean BWs of both the recovery and constant groups were reduced
compared with vehicle controls from the 8th–11th days of dosing; however, by the 12th day of dosing, BWs of the recovery group had returned to control levels.
(B, C) Effects of various concentrations of PFOA, given for 15 days via drinking water, on mean BW in female C57BL/6N mice. (B) Mean BW of the 30-mg PFOA/kg
dose group was reduced compared with vehicle controls beginning the 8th day of dosing; mean BW of the 15-mg PFOA/kg dose group was reduced relative to
vehicle controls 1 day after dosing ended. (C) Mean BWs of mice exposed to 0.94–7.5 mg PFOA/kg did not change by dose within the 15-day exposure period.
*p < 0.05.
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*was 104 ± 14.4% and 89.4 ± 11.0% for low
and high (control) QC sera, respectively, and
104 ± 11.1% and 98.0 ± 10.2% for low and
high (dosed) sera, respectively. Average coefﬁ-
cients of variation for replicate analysis of
unknown (n = 20) sera for both control and
dosed animals was 11.7%.
Samples were run in batches that included
double blanks (solvent blank), a method
blank, matrix blank (blank serum), standards,
QC samples, and unknowns in sequence.
Standards were run at the beginning and end
of the analytical batch, and QC samples were
interspersed in the analytical batch. PFOA was
monitored via the transition 413-369 and for
the 13C-PFOA 415-370. Samples were run
using an isocratic mobile phase of 30:70
2 mM ammonium acetate:acetonitrile at a
ﬂow of 200 µL/min with a 10-µL sample vol-
ume. Samples were run through a Sunﬁre C18
column (50 × 3.0 mm, 5 µm particle size;
Waters) and appropriate guard column for
separation. Analytes were integrated using the
equipment software and corrected if necessary
by the operator. Quantitation was done by
making standard curves of concentration ver-
sus area ratios of internal standard response to
analyte response. All standard curves had r2
values > 0.99.
PFOA dosing solutions. Dosing solutions
of PFOA dissolved in deionized water were
analyzed from animal-watering apparatus to
ensure no appreciable losses of PFOA occurred
between changing solutions. Dosing solutions
were diluted to bring PFOA concentrations
into an acceptable range for LC-MS/MS analy-
sis with deionized water and analyzed as above
by LC-MS/MS. Concentrations of PFOA in
dosing solutions did not change appreciably
over a 2-week period (data not shown).
Benchmark dose analysis. We pooled IgM
serum titer data from two replicate experi-
ments that identified both a LOAEL and
NOAEL and analyzed them to determine the
benchmark dose (BMD) and lower bound of
the 95% confidence interval, using software
developed by the U.S. EPA (2000). One stan-
dard deviation (1SD) from the control mean
was chosen as the benchmark response
(BMD1SD) level. The current BMD technical
guidelines (U.S. EPA 2000) suggest 1SD from
the control mean as a benchmark response
level for continuous data in the absence of
additional information such as a minimal level
of change in the end point that is generally
considered to be biologically signiﬁcant. Effects
on serum titer were modeled using Hill,
power, and ﬁrst, second, and third degree poly-
nomial models for homogeneous data.
Statistical analysis. All data are presented
as mean ± SE. Statistical analyses were per-
formed with the SAS System (SAS Institute,
Cary, NC). We used analysis of variance
(ANOVA) to analyze immune responses by
dose; when appropriate, linear regressions
were used to determine dose response. When
ANOVA indicated a statistically significant
treatment effect, we made individual post hoc
comparisons using Tukey’s test and the least
squares means t-test with a Tukey’s adjust-
ment for controlling the family-wise error
rate. A repeated-measures ANOVA was used
to analyze BW changes over time and dose.
Statistical significance was determined using
an α of 0.05.
Results
Recovery study. Serum PFOA concentrations.
In the recovery and constant groups, respec-
tively, the fold difference in mean PFOA con-
centration relative to vehicle controls was
2,582 and 8,125 1 day after dosing ended, and
1,933 and 2,753 15 days after dosing ended
(Table 1). Mean differences in PFOA concen-
tration between vehicle and cage controls did
not differ statistically, although the mean value
for the cage controls 15 days after exposure
ended (614.9 ng PFOA/mL) indicated a
source of PFOA contamination for this group
of animals. However, levels of PFOA in all
plastic materials used during the experiment
were at or below the limit of detection.
Water consumption and body and liver
weights. Water consumption per cage did not
vary statistically between vehicle controls and
dosed groups (data not shown). From the 8th
day of dosing through the 11th day of dosing,
mean BW of animals receiving 30 mg
PFOA/kg/day (recovery and constant) was
reduced by approximately 8% (p < 0.05) rela-
tive to BW of animals receiving vehicle
(Figure 2A). Two days after PFOA dosing
ended, the mean BW of animals from the
recovery group was equivalent to the weights
of the vehicle control group. Weights of the
constant group remained reduced by approxi-
mately 10.5% relative to the weights of the
vehicle control group until the end of dosing
(p < 0.05). Fifteen days after exposure ended,
the BW of animals from all groups were sta-
tistically equivalent (data not shown). Relative
liver weights for both the constant and recov-
ery groups were elevated (p < 0.05) by 64%
compared with controls 1 day after exposure
ended and by approximately 54% 15 days
after exposure ended (data not shown).
Lymphoid organ weights. One day after
dosing ended, mean spleen and thymus
weights were reduced in animals exposed to
30 mg PFOA/kg compared with unexposed
animals (Table 2). Absolute and relative
spleen weights were approximately 24% lower
in the recovery group and approximately 48%
lower in the constant group (p < 0.05).
Absolute and relative thymus weights were
approximately 36% lower in the recovery
group and approximately 79% lower in the
constant group (p < 0.05). By 15 days after
the end of exposure, both spleen and thymus
weights were statistically equivalent to control
weights.
Immune responses. SRBC-specific IgM
antibody titers (Figure 3A) were reduced
(p < 0.05) relative to controls by nearly 20%
in both the recovery and the constant groups.
Immunotoxicity of PFOA
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Table 2. Lymphoid organ weights (mean ± SE) of female mice exposed to PFOA for 15 days, 1 or 15 days postdosing (PD).
Spleen weight (mg) Relative spleen weight Thymus weight (mg) Relative thymus weight
Recovery studya 1 day PD 15 days PD 1 day PD 15 days PD 1 day PD 15 days PD 1 day PD 15 days PD
Cage control 91.9 ± 7.62 89.5 ± 4.12 4.84 ± 0.32 4.55 ± 0.20 49.1 ± 2.06 50.1 ± 1.89 2.61 ± 0.078 2.55 ± 0.075
Vehicle control 90.6 ± 2.13 82.6 ± 4.50 4.80 ± 0.11 4.36 ± 0.19 49.4 ± 1.36 20.1 ± 1.97 2.62 ± 0.071 2.66 ± 0.10
Recovery 68.2 ± 5.13* 82.9 ± 3.76 3.72 ± 0.37* 4.16 ± 0.13 31.3 ± 7.42* 56.3 ± 4.74 1.69 ± 0.41* 2.83 ± 0.22
Constant 43.8 ± 2.28* 72.8 ± 5.18 2.77 ± 0.12* 3.72 ± 0.22 9.6 ± 1.41* 43.4 ± 5.34 0.60 ± 0.081* 2.22 ± 0.28
Dose–response study I (PFOA mg/kg/day)
0 89.9 ± 2.59 86.3 ± 2.86 4.63 ± 0.17 4.16 ± 0.13 62.1 ± 2.60 61.3 ± 2.44 3.19 ± 0.14 2.97 ± 0.14
3.75 93.9 ± 12.12 95.2 ± 1.73 4.57 ± 0.55 4.43 ± 0.084 62.9 ± 2.44 67.3 ± 2.29 3.09 ± 0.13 3.13 ± 0.11
7.5 78.5 ± 2.35 92.2 ± 2.24 3.80 ± 0.12 4.35 ± 0.078 59.0 ± 3.14 64.0 ± 2.17 2.88 ± 0.18 3.01 ± 0.077
15 60.8 ± 1.77* 95.3 ± 2.29 3.18 ± 0.068* 4.43 ± 0.078 42.7 ± 2.94* 72.3 ± 1.49* 2.24 ± 0.15* 3.37 ± 0.080
30 47.5 ± 2.62* 79.3 ± 4.19 2.76 ± 0.12* 3.68 ± 0.17 28.2 ± 3.68* 69.3 ± 3.04 1.62 ± 0.21* 3.23 ± 0.14
Dose–response study II (PFOA mg/kg/day)
0 102.1 ± 4.37 95.1 ± 2.94 4.9 ± 0.18 4.43 ± 0.11 63.1 ± 2.74 58.0 ± 3.74 3.02 ± 0.13 2.69 ± 0.16
0.94 102.1 ± 3.72 99.9 ± 3.12 4.9 ± 0.14 4.65 ± 0.11 64.9 ± 1.32 65.2 ± 2.27 3.16 ± 0.07 3.04 ± 0.096
1.88 94.6 ± 3.42 94.7 ± 4.29 4.6 ± 0.15 4.36 ± 0.20 68.7 ± 2.18 66.3 ± 2.24 3.32 ± 0.10 3.07 ± 0.12
3.75 85.8 ± 2.56* 100.7 ± 2.01 4.1 ± 0.11* 4.62 ± 0.086 58.5 ± 1.71 64.9 ± 2.64 2.80 ± 0.08 2.98 ± 0.12
7.5 82.8 ± 3.32* 103.0 ± 2.73 4.1 ± 0.15* 4.69 ± 0.098 56.9 ± 2.44 67.3 ± 2.20 2.81 ± 0.13 3.08 ± 0.11
aOrgans from recovery groups were collected 6 or 20 days after the last PFOA dose was administered. *Statistically different from control groups (p< 0.05).DeWitt et al.
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SRBC-speciﬁc IgG antibody titers (Figure 4A)
and DTH responses (data not shown) were
not statistically altered by exposure to PFOA.
Dose–response study I. Serum PFOA
concentrations. One day after dosing ended,
the mean PFOA concentration of drinking
water was between 7.5 × 104 (3.75 mg
PFOA/kg/day) and 1.6 × 105 ng/mL (30 mg
PFOA/kg/day) (Table 1). Linear regression
analysis indicated that PFOA concentrations
among the dose groups increased dose
dependently (r2 = 0.7711). Fifteen days after
dosing ended, the mean PFOA concentrations
had decreased to 3.5 × 104 ng PFOA/mL in
the 3.75-mg PFOA/kg/day dose group and
5.3 × 104 ng PFOA/mL in the 30-mg
PFOA/kg/day dose group. Within 2 weeks, the
mean PFOA concentration was approximately
50% lower relative to the 1-day postdosing
concentrations in the two low dose groups
(3.75 and 7.5 mg PFOA/kg/day) and approxi-
mately 65% lower in the two high dose groups
(15 and 30 mg PFOA/ kg/day). The mean
PFOA concentrations in the vehicle control
groups were between 54.3 ng PFOA/mL 1 day
postdosing and 156.4 ng PFOA/mL 15 days
postdosing. The 15-day postdosing PFOA
vehicle control concentration indicated a
source of PFOA contamination or transfer of
PFOA from another cage; however, as with the
cage controls in the recovery study, levels of
PFOA in all plastic materials used during the
experiment were at or below the limit of detec-
tion on the instrument.
Water consumption and body and liver
weights. Water consumption per cage did not
vary statistically between vehicle controls and
dosed groups (data not shown). From the 8th
day of dosing through the end of the dosing
period, mean BW (Figure 2A) of animals
drinking 30 mg PFOA/kg/day was reduced by
6–15% (p < 0.05) relative to BW of animals
drinking vehicle water. The BW of animals
drinking 15 mg PFOA/kg/day was reduced by
nearly 6% at the end of the 15-day dosing
period. BWs of animals drinking 30 mg
PFOA/kg were equivalent to those of control
animals within 8 days after dosing ended (data
not shown). Relative liver weights for all dosed
groups were elevated (p < 0.05) compared
with controls by 51–70% 1 day after exposure
ended and 45–61% 15 days after exposure
ended (data not shown).
Lymphoid organ weights. One day after
exposure ended, mean spleen and thymus
weights of animals exposed to 15 or 30 mg
PFOA/kg/day were reduced relative to unex-
posed animals (Table 2). Absolute and relative
spleen weights were approximately 32% lower
in the 15-mg PFOA/kg/day group and 44%
lower in the 30-mg PFOA/kg/day group
(p < 0.05). Absolute and relative thymus
weights were approximately 31% lower in the
15-mg PFOA/kg/day group and 52% lower in
the 30-mg PFOA/kg/day group (p < 0.05).
We observed no changes to lymphoid organ
weights at any of the lower doses. Fifteen days
postdosing, both spleen and thymus weights
were statistically equivalent to control weights.
The exception was the 15-mg PFOA/kg/day
group, in which the mean absolute thymus
weight was 18% greater (p < 0.05) relative to
control weights.
Immune responses. All doses of PFOA
reduced SRBC-specific IgM antibody titers
(Figure 3B) relative to controls (p < 0.05) by
between 11 (3.75 mg PFOA/kg/day) and
29% (30 mg PFOA/kg/day). Therefore, a
NOAEL for suppressed IgM antibody produc-
tion was not identified with this study. We
identified 3.75 mg PFOA/kg/day as the
LOAEL for suppressed IgM antibody produc-
tion. SRBC-specific IgG antibody titers
(Figure 4B) were not reduced relative to con-
trols at any dose tested; however, titers were ele-
vated relative to controls by approximately 13%
in both the 3.75- and 7.5-mg PFOA/kg/day
groups. DTH responses (data not shown) were
not statistically altered by exposure to the tested
doses of PFOA.
Dose–response study II. Water consump-
tion and body and liver weights. Water con-
sumption per cage did not vary statistically
between vehicle controls and dosed groups
(data not shown). BWs of animals exposed to
0.94–7.5 mg PFOA/kg/day did not statistically
Figure 3. Effects of PFOA exposure on SRBC-speciﬁc IgM antibody titers (mean ± SE) in female C57BL/6J (A) or C57BL/6N (B,C) mice. OD, optical density. (A) PFOA
was given for 10 days (PFOA recovery) or 15 days (PFOA constant) via gavage; IgM antibody titers were suppressed in both exposed groups compared with con-
trols. (B,C) PFOA was given for 15 days via drinking water. (B) IgM antibody titers were suppressed relative to controls for all tested doses. (C) IgM antibody titers
were suppressed relative to controls at the two highest doses. Means with different letters are statistically different (p < 0.05).
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Figure 4. Effects of PFOA exposure on SRBC-speciﬁc IgG antibody titers (mean ± SE) in female C57BL/6J (A) or C57BL/6N (B,C) mice. OD, optical density. (A) PFOA
(30 mg/kg) was given for 10 days (PFOA recovery) or 15 days (PFOA constant) via gavage. No statistical effect on IgG antibody titers was detected. (B, C) PFOA
given for 15 days via drinking water. (B) IgG antibody titers were elevated compared with controls at 3.75 and 7.5 mg/kg. (C) IgG antibody titers were elevated
compared with controls at 3.75 mg/kg. Means with different letters are statistically different (p < 0.05)
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abdiffer from BW of control animals during the
dosing period (p < 0.05; Figure 2B). Relative
liver weights for all dosed groups were elevated
(p < 0.05) relative to controls by 35–60%
1 day after exposure ended and 22–45%
15 days after exposure ended (data not shown).
Lymphoid organ weights. One day after
exposure ended, mean spleen weights of ani-
mals exposed to 3.75 or 7.5 mg PFOA/kg/day
were reduced relative to unexposed animals
(Table 2). Absolute and relative spleen
weights were approximately 16% lower in the
3.75-mg PFOA/kg/day group and 18% lower
in the 7.5-mg PFOA/kg/day group (p < 0.05).
Fifteen days postdosing, spleen weights of
these groups were statistically equivalent to
control weights. No other statistical changes in
lymphoid organ weights were observed.
Immune responses. Exposure to 3.75 or
7.5 mg PFOA/kg/day reduced SRBC-speciﬁc
IgM antibody titers (Figure 3C) by approxi-
mately 7% relative to controls (p < 0.05). We
identiﬁed a NOAEL of 1.88 mg PFOA/kg/day
for suppressed IgM antibody production; these
results supported the LOAEL of 3.75 mg
PFOA/kg/day from dose–response study I.
SRBC-speciﬁc IgG antibody titers (Figure 4C)
were elevated by 14% relative to controls in the
3.75 mg PFOA/kg/day group. DTH responses
(data not shown) were not statistically altered
by exposure to the tested doses of PFOA.
BMD analysis. All models properly
described the response and detected signifi-
cant differences between dose levels. Although
the lowest Akaike information criterion (AIC)
number and the smallest scaled residual value
at the BMD were returned by the Hill model,
the model failed to detect a lower bound to
the BMD, perhaps because the selected
benchmark response fell outside the range of
possible asymptote values. Results of the sec-
ond-degree polynomial model were therefore
chosen as the best representation of the data,
with an AIC of –59.10 and a scaled residual
value of 0.24. The model returned a BMD1SD
of 3.06 mg/kg/day and a lower 95% confi-
dence limit of 1.75 mg/kg/day.
Discussion
In this study, we evaluated lymphoid organ
weights and two adaptive immune responses in
adult C57BL/6J or C57BL/6N mice following
exposure to the PFOA, a PFAA. Exposure to
15 or 30 mg PFOA/kg/day after 10 or 15 days
of exposure (via gavage or drinking water)
statistically reduced relative spleen and thy-
mus weights and SRBC-specific IgM anti-
body titers. In addition, 3.75 and 7.5 mg
PFOA/kg/day also reduced the production of
SRBC-speciﬁc IgM antibodies when given via
drinking water for 15 days. This is in contrast
to the results of Yang et al. (2002), who
reported that the IgM response was suppressed
only by constant exposure to PFOA. Our data
therefore suggest that in rodents, adaptive
immune functions may be sensitive to PFOA
at concentrations ≥ 3.75 mg/kg/day, a dose that
resulted in a serum concentration of 7.5 ×
104 ng/mL. This concentration is approxi-
mately 50- to 100-fold greater than the concen-
tration of PFOA reported in sera of humans
living near a PFOA production facility.
Within the past decade, considerable atten-
tion has been paid to PFOA and related
PFAAs because of their presence in humans,
biota, and environmental media. However, the
toxicokinetics and mode(s)/mechanism(s) of
action for toxicologic effects have not yet been
thoroughly described. Although immuno-
suppression has been identiﬁed as an end point
of concern by the U.S. EPA, a paucity of data
exists to corroborate the few studies that report
immune suppression after exposure to PFOA.
The changes that we observed in lymphoid
organ weights for our recovery study and in
dose–response study I were consistent with
previous reports of PFOA-induced immuno-
modulation (Yang et al. 2000, 2001). Both
laboratories observed reductions in lymphoid
organ weights at 15 and 30 mg PFOA/kg/day,
but not at lower doses, and also demonstrated
that lymphoid organ weights recovered to con-
trol levels within 10 (Yang et al. 2001) or
15 days after exposure ended. At doses of 15
and 30 mg PFOA/kg/day, mean serum PFOA
concentrations for our animals were between
5.0 × 104 ng/mL (dose–response study I) and
6.8 × 104 ng/mL (recovery study) 15 days after
exposure ended, indicating that circulating
PFOA at this concentration was not sufﬁcient
to maintain suppressed lymphoid organ
weights.
The data from our dose–response study I
indicated that reductions in IgM antibody
titers occurred at lower doses and PFOA
serum concentrations than those required to
reduce lymphoid organ weights. In dose–
response study I, lymphoid organ weight
reductions occurred only at doses of 15 and
30 mg PFOA/kg/day, corresponding to mean
PFOA serum concentrations of 1.3 × 105 and
1.6 × 105 ng/mL, respectively. IgM antibody
titers were reduced at a dose of 3.75 mg
PFOA/kg/day and a PFOA serum concentra-
tion of 7.5 × 104 ng/mL, which we identiﬁed
as a LOAEL. Therefore, because statistical
reductions in lymphoid organ weights did not
coincide with effects on antibody synthesis,
we conclude that lymphoid organ atrophy is
not a sensitive indicator of PFOA-induced
immune dysfunction.
In both dose–response studies, we identi-
ﬁed a LOAEL of 3.75 mg PFOA/kg/day, and
in dose–response study II, we identified a
NOAEL of 1.88 mg PFOA/kg/day for IgM
antibody responses. Although Yang et al.
(2002) evaluated the effects of PFOA on sev-
eral immune system parameters, they used
only one dose (30 mg PFOA/kg/day). At this
PFOA dose, Yang et al. (2002) reported sup-
pression of horse red blood cell (HRBC)–
speciﬁc IgM and IgG antibody titers, a reduc-
tion in the number of spleen cells secreting
HRBC-speciﬁc IgM and IgG antibodies, and
a reduction in the proliferative response of
spleen cells after stimulation; however,
methodologic discrepancies make interpreta-
tion of their data difﬁcult. For example, Yang
et al. (2002) reported HRBC-speciﬁc plaques
and IgM/IgG antibody titers in unimmunized
animals and measured IgG after only a single
immunization. These discrepancies suggest
that the magnitude of the suppression due to
PFOA exposure may differ from what was
reported by Yang et al. (2002). Our data sup-
port suppression of antibody titers at a dose of
30 mg/kg/day (Yang et al. 2002) and indicate
that suppression of the primary antibody
response occurs at a dose that is approxi-
mately 8-fold lower than reported by Yang
et al. (2002). Application of BMD analysis of
pooled low-dose datasets (0, 0.94, 1.88, 3.75,
and 7.5 mg/kg/day) returned a BMD of
3.06 mg PFOA/kg/day, with a lower bound
of 1.75 mg PFOA/kg/day. The lower bound
value is selected as the point of departure by
risk assessors, and is used to set reference
doses (RfD) or concentrations. An advantage
of the BMD approach is that all data from
the dose response are used, and the derived
dose does not depend on investigator-selected
dose intervals used to identify LOAELs and
NOAELs. Values derived by all BMD models
were within 1–2 mg PFOA/kg/day, suggest-
ing that a dose in this range is a reasonable
point of departure for calculating an
immunotoxicity-based RfD.
We also determined that IgG responses
were affected by PFOA exposure, although in
our studies, IgG titers were increased at lower
doses and were similar to control responses at
the higher doses. These results are in contrast to
suppression of the IgG response reported by
Yang et al. (2002) and by Cunard et al. (2002),
who reported that exposure to the potent per-
oxisome proliferator-activated receptor α
(PPAR-α) agonist and the peroxisome prolifer-
ator WY14,643 suppressed IgG antibody
responses and reduced splenocyte number.
However, our results may reﬂect recovery and
rebound of IgG synthesis at lower doses, and
progressive—but not complete—recovery from
PFOA-induced suppression at higher exposure
levels. Because our data reﬂect function approx-
imately 2 weeks after exposure ended, addi-
tional studies will be conducted in which the
booster immunization is delayed; this modiﬁca-
tion may help to resolve the apparent aug-
mented IgG response in exposed animals. In
addition, the antibody titer and plaque-forming
cell results reported by Yang et al. (2002) do
not reﬂect IgG levels collected at peak response
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or following booster immunizations; they col-
lected IgG data after only a single immuniza-
tion and at the same time as IgM data.
Serum levels of PFOA in the general
human population have been reported to be
approximately 5 ng/mL (Calafat et al. 2007)
and approximately 5 × 102 ng/mL (Emmett
et al. 2006) after environmental/occupational
exposures. Using our LOAEL of 3.75 mg
PFOA/kg/day for suppressed IgM antibody
production and the associated serum PFOA
concentration of 7.5 × 104 ng/mL, the margin
of exposure for suppressed IgM antibody pro-
duction is approximately 150 for environmen-
tal/occupational exposures and 15,000 for the
general human population. However, we
observed changes in IgG antibody titers at a
serum PFOA concentration as low as 3.5 ×
104 ng/mL, which is a margin of exposure of
only 70 for environmentally/occupationally
exposed populations. Our antibody data and
the data reported by Yang et al. (2000, 2001,
2002) suggest that the immune system is a tar-
get of PFOA and that the recommendation by
the U.S. EPA Science Advisory Board (U.S.
EPA 2006) to consider immune system effects
for a quantitative PFOA risk assessment
is warranted.
We are currently exploring mechanisms by
which PFOA may reduce IgM antibody titers
at a lower dose than that at which signiﬁcant
effects on lymphoid organ weights are
observed, as well as the relationship between
PFOA-induced peroxisome proliferation
and immunomodulation in C57BL/6 mice.
Peroxisome proliferation, as evidenced by the
liver hepatomegaly that we observed at all
tested doses, occurred at lower doses than
required to reduce lymphoid organ weights or
antibody production. We are evaluating
immune responses in C57BL/6 mice lacking
PPAR-α, a receptor that is activated by PFOA,
to determine the role of PFOA-induced
PPAR-α activation in immunomodulation.
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